Novartis

Novartis delivers solid sales and core operating income growth with strong pipeline progress in Q3; reaffirms FY 2025 guidance

Sales growth was driven by continued strong execution on priority brands including Kisqali (+68% cc), Kesimpta (+44% cc), Pluvicto (+45% cc) and Scemblix (+95% cc) Core operating income margin 1 was ...
Novartis

Novartis ianalumab first drug to reduce disease activity and patient burden in Sjögren’s disease Phase III trials

Basel, October 29, 2025 – Novartis today presented new ianalumab data in Sjögren’s disease, the second most prevalent rheumatic autoimmune disease 2, at a late-breaker presentation during the American ...
Novartis

Careers at Novartis in Slovenia

At Novartis, we innovate, develop and operate on a vast scale. You can be part of it. Join our creative community of professionals and you will find opportunities to make an unprecedented impact – on ...
Novartis

Career Search

Explore opportunities with Novartis and Sandoz below. For additional roles with Novartis Gene Therapies (formerly AveXis) visit the GTx Career Search.
Novartis

Novartis Indonesia Leadership

Our leaders in Indonesia are experienced professionals, both in global and local pharmaceutical industry.
Novartis

Novartis agrees to acquire Avidity Biosciences, an innovator in RNA therapeutics, strengthening its late-stage neuroscience pipeline

Transaction strengthens neuroscience franchise for Novartis with three late-stage programs that address genetic neuromuscular diseases; ...
Novartis

Novartis Cosentyx® meets primary and all secondary endpoints in Phase III trial in patients with polymyalgia rheumatica (PMR)

Cosentyx® (secukinumab) achieved statistically significant and clinically meaningful sustained remission vs placebo at Week 521 Trial showed reduction in annual cumulative steroid dose vs placebo ...
Novartis

Novartis Scemblix® receives positive CHMP opinion for the treatment of adults with newly diagnosed CML

If approved, Scemblix will be indicated for adults with chronic myeloid leukemia (CML), both newly diagnosed and previously treated, expanding access to four times as many patients in Europe Scemblix ...
Novartis

Novartis showcases significant immunology advancements in ACR congress with new data in complex autoimmune diseases

About Novartis Immunology At Novartis, we’re advancing bold science for autoimmune diseases, where meaningful therapeutic progress has long stalled. With a growing legacy of first-in-class innovation ...
Novartis

Novartis Fabhalta® (iptacopan) meets Phase III primary endpoint, slows kidney function decline in patients with IgA nephropathy (IgAN)

In APPLAUSE-IgAN final analysis, Fabhalta demonstrated statistically significant, clinically meaningful improvement in estimated glomerular filtration rate (eGFR) slope vs. placebo over two years 1 ...
Novartis

ノバルティスのレミブルチニブ、特発性の慢性蕁麻疹（CSU）に対して唯一の経口ブルトン型チロシンキナーゼ（BTK）阻害剤として ...

この資料は、ノバルティス（スイス・バーゼル）が2025年9月30日（現地時間）に発表したものを日本語に翻訳（要約）したもので、参考資料として提供するものです。資料の内容および解釈 ...
Novartis

Zaposlitev v Novartisu v Sloveniji

V Novartisu spodbujamo inovativnost in razvoj ter delujemo na številnih področjih. Tudi vi lahko postanete del tega, del naše zgodbe. Pridružite se naši ustvarjalni skupnosti strokovnjakov in našli ...